PI: Sierra Pond IRB Exemption: 00164238

1 2

#### Identifying barriers to genetic testing in subspecialty cardiac care

- 3 Primary author: Sierra Pond, MS, University of Utah Graduate Program of Genetic Counseling
- 4 Author 1: Genevie Echols, RCIS, SADS Foundation
- 5 Author 2: Martin M Tristani-Firouzi, MD, University of Utah
- 6 Author 2: Susan P Etheridge, MD, St Luke's Boise, ID
- 7 Author 3: Hannah S Anderson, LCGC, University of Utah
- 8 Author 4: Briana L Sawyer, LCGC, University of Utah
- 9

#### 10 ABSTRACT

- 11 <u>Background</u>
- 12 The utility of genetic testing in cardiovascular medicine is well-established in expert consensus
- 13 statements for optimizing patient care. However, significant genetic testing care gaps persist for
- 14 patients with inherited cardiovascular conditions.

#### 15 <u>Objective</u>

- 16 This study aimed to understand why genetic testing care gaps in cardiovascular medicine exist by
- 17 evaluating cardiovascular providers' opinions and use of genetic testing.

#### 18 <u>Methods</u>

- 19 We developed and administered an anonymous survey to cardiovascular providers delivering direct
- 20 patient care in the United States. Participants were contacted in collaboration with the Sudden
- 21 Arrhythmia Death Syndromes (SADS) Foundation.

#### 22 <u>Results</u>

- 23 A total of 111 individuals completed the survey representing the following specialties:
- 24 electrophysiology (55%, n=61), general cardiology (10.8%, n=12), imaging (7.2%, n=8), heart
- 25 failure/transplant (6.3%, n=7), interventional cardiology (6.3%, n=7), fetal cardiology (5.4%, n=6),
- and other (9%, n=10). Eighty-six percent of respondents (n=97) stated genetic testing is 'very
- 27 relevant' in the care of their patients. Eighty percent of electrophysiologists reported ordering
- 28 genetic testing a few times a month or more. Navigating insurance authorization and billing
- 29 procedures was an identified area of discomfort by 47.7% of respondents (n=53). Overall,
- 30 cardiovascular provider specialty was shown to impact how often genetic testing is ordered. Provider
- 31 work setting was shown to impact opinion of the utility of genetic testing for family screening,
- 32 opinion of the utility of genetic testing for medication and device management, and how often
- **33** genetic testing is ordered.

### 34 <u>Conclusions</u>

- 35 The results of this study support targeted provider education to increase the uptake of genetic
- 36 testing for patients with inherited cardiovascular conditions.
- 37
- 38
- 39
- 40
- 41
- 42
- 43 44
- 44

#### 46 KEYWORDS

47 Cardiovascular medicine, genetic testing, electrophysiology, insurance

PI: Sierra Pond IRB Exemption: 00164238

#### 48 INTRODUCTION

49 Genetic testing as a diagnostic and management tool is a key component of patient care in the

- 50 emergence of precision medicine. Inherited cardiac conditions are associated with substantial
- 51 morbidity and mortality with known benefits from genetic testing to manage patients with inherited
- 52 cardiac conditions [1-4]. Examples of the diagnostic utility of genetic testing in cardiovascular
- 53 medicine include the ability to establish a molecular clinical diagnosis, earlier diagnosis,
- 54 characterization of a patient's syndrome subtype, elimination of other suspected conditions, and
- 55 initiation of family cascade screening once a proband's genetic variant has been identified [1, 3, 5-8].
- The utility of genetic testing in cardiovascular management can be divided into two categories:
  prognostic and therapeutic. Examples of prognostic management enabled by genetic testing for
- prognostic and therapeutic. Examples of prognostic management enabled by genetic testing for
  cardiovascular patients include genotype-phenotype correlations [9] and anticipating patient
- 59 prognosis with specific recommendations about physical activity and other lifestyle modifications
- 60 such as drug avoidance [2, 10, 11]. Additionally, genetic testing facilitates therapeutic management
- 61 decisions for cardiovascular patients regarding tailored pharmacological and procedural decisions
- 62 [12, 13] and cardiac device management [12].
- 63

64 Guidelines and expert consensus statements supporting the use of genetic testing in cardiovascular

conditions have been reported in the literature since 2011 [14, 15]. Since then, the specific languagesurrounding the use of genetic testing for patients with suspected cardiovascular conditions has

67 evolved significantly [16] with new evidence to support and strengthen recommendations.

68 Consensus statements and expert working groups on heritable cardiac conditions now encompass a

69 wide range of diagnoses including familial hypercholesterolemia [17], adult congenital heart disease

70 [18], hypertrophic cardiomyopathy [19], channelopathies [20], and arrhythmogenic cardiomyopathy

**71** [21].

72

73 The benefits of genetic testing in cardiology are not universally accepted and applied [22].

74 According to a 2023 statement from the American College of Cardiology, "patients with certain

75 inherited cardiovascular conditions rarely receive genetic testing recommended by clinical practice

76 guidelines" [23]. Genetic testing uptake is below 10% across all inherited cardiac conditions [23-25],

- 77 which is in stark comparison to the strong recommendation of its utility. Previous research
- 78 identified barriers to the use of genetic testing in other disciplines outside of cardiovascular
- 79 medicine. Such barriers exist at the provider level, the clinic level, and the societal level at large,
  80 leaving genetic testing an 'untapped resource' [26] for patient care. Literature on barriers to genetic

80 leaving genetic testing an untapped resource [20] for patient care. Enterature on barners to genetic 81 testing in other disciplines including cancer and neurology exists at length. Previous research on the

barriers to the use of genetic testing in the world of subspecialty cardiac care focused on the patient

Barners to the use of genetic testing in the world of subspecialty cardiac care focused on the patientperception of genetic testing [27] and practitioners' confidence and desires for education in

- 84 cardiovascular and sudden cardiac death genetics [28]. Past research has also demonstrated that there
- 85 is no significant psychological harm done to patients who undergo cardiovascular genetic testing86 [29].
- 86 87

88 It remains unknown in cardiovascular medicine how provider specialty influences a provider's

89 opinion of, use of, and access to genetic testing. This project aims to assess the opinions of

90 cardiovascular providers in various subspecialties on genetic testing; how cardiovascular providers

91 implement genetic testing in their practice; and what barriers cardiovascular providers identify to

- 92 their use of genetic testing. As a secondary aim, this project also aimed to compare these barriers
- 93 among different provider types to assess differences between provider groups.
- 94

PI: Sierra Pond IRB Exemption: 00164238

#### 95

#### 96 METHODS

#### 97 Study Population

98 To assess the opinions of, use of, and barriers to the use of genetic testing in subspecialty cardiac

99 care, a one-time quantitative survey was developed and administered to licensed cardiovascular

100 providers who engage in direct patient care in the United States. To meet the inclusion criteria for

101 survey participation, participants were required to self-identify as a physician, physician assistant,

102 nurse, or advanced practice nurse (listed as MD, DO, PA, RN, or APRN in the survey). Genetic

103 counselors and medical geneticists were intentionally excluded from participation in the survey to104 reduce bias.

105

#### 106 Survey Development

107 Questions were designed to elicit cardiovascular providers' opinions of, use of, and access to genetic

**108** testing. Survey development was guided by previous research [28]. Our survey consisted of five

109 main sections with twenty-nine total questions: (1) inclusion criteria, (2) provider opinions on

**110** genetic testing utility, (3) provider-reported implementation of genetic testing in their practice, (4)

**111** provider-identified barriers to the use of genetic testing in their practice, and (5) demographics.

112 Survey questions were mainly Likert-scale and categorical, asking participants to define their opinion

113 of genetic testing, their use of genetic testing, and their comfort with activities related to genetic

114 testing. The survey was piloted by three pediatric cardiologists, three genetic counselors, and three

**115** members of the Sudden Arrhythmia Death Syndromes (SADS) Foundation before dissemination.

116

#### 117 Survey Administration

118 The anonymous electronic survey was administered via RedCap Software hosted at the University of

119 Utah [30, 31]. The survey was fielded between January and April 2024. Participants provided written

120 informed consent at the start of the survey. The study was approved and granted exemption status

121 by the University of Utah's Institutional Review Board (00164238).

122

**123** Participants were contacted via email recruitment across the United States with integral help from

124 the SADS Foundation. The recruitment email explained the intent of the research as well as the

anonymous response platform. Providers from the SADS Foundation Physician Referral Network

126 (PRN) were contacted first to establish contact with major healthcare institutions across the United

**127** States. Participants were encouraged to disseminate the survey within their professional networks.

**128** Professional societies were also targeted for contact including the Heart Failure Society of America

**129** and the Heart Rhythm Society. An intentional approach was taken to recruit participants from a

130 representative group of cardiovascular subspecialties, patient age ranges, geographic regions, and a

- **131** diverse range of workplace settings.
- 132

#### 133 Statistical Analysis

134 Means, standard deviations, and proportions were calculated for categorical variables. Chi-squared

tests were used to compare categorical variables. Testing correction using the Bonferroni method

was then performed as multiple testing comparisons were performed. The adjusted significance level

- **137** was P < 0.0022. Data analysis was performed with Python software version (3.9.5). Data are available
- 138 upon request.
- 139
- 140
- 141

PI: Sierra Pond IRB Exemption: 00164238

#### 142

# 143 RESULTS

### 144 Demographics

145 A total of 125 individuals submitted responses to the survey. Twelve of these responses were

- **146** excluded as they did not meet inclusion criteria or were incomplete. This resulted in 111 total
- 147 responses for inclusion in the study analysis. The demographic characteristics of the study
- 148 participants are summarized in Table 1. Most survey respondents (55%; n=61) reported working in
- 149 the specialty of electrophysiology. Other major provider specialties included general cardiology
- 150 (10.8%; n=12), imaging (7.2%; n=8), heart failure/transplant (6.3%; n=7), and interventional
- **151** cardiology (6.3%; n=7). Most survey respondents (43.2%; n=48) reported seeing a mix of pediatric
- **152** and adult cardiovascular patients. Thirty-two percent of respondents (n=36) reported seeing
- **153** pediatric cardiovascular patients only; 22.5% of respondents (n=25) reported seeing adult
- 154 cardiovascular patients only; and 1.8% of respondents (n=2) reported seeing prenatal cardiovascular
- **155** patients. The geographic region and work setting of participants was primarily urban (82.9%; n=92)
- **156** at university medical centers (78.4%, n=87). Most survey respondents (52.2%, n=58) reported
- 157 having been in practice for more than fifteen years. Due to the wide variety of recruitment
- 158 techniques, a survey response rate is not possible to calculate.

159

#### PI: Sierra Pond IRB Exemption: 00164238

Characteristics	Number of Respondents, N
Time in Practice	- <u></u>
Still in training	9
5 Years	8
5-10 Years	16
10-15 Years	20
>15 Years	58
Work Setting	
Private Group Practice	7
Private Solo Practice	0
University Medical Center	87
Private Hospital/Medical Facility	9
Public Hospital/Medical Facility	7
Diagnostic Laboratory/Testing Laboratory	0
Post Mortem	0
Other	1
Geographic Region of Work	
Urban	92
Suburban	18
Rural	1
Provider Reported Specialty	
Electrophysiology	61
Heart Failure/Transplant	7
Interventional	7
Fetal Cardiology	6
Imaging	8
Pulmonary Hypertension	0
Dyslipidemia	0
CICU	3
General Cardiology	12
Cardiothoracic Surgery	1
Other, Not Listed	6
Age Range of Patients Seen	
Pediatrics	36
Adult	25
Both Pediatric and Adult	48
Prenatal	2

160

**TABLE 1.** Demographic Characteristics of Study Participants

Participants were asked a handful of demographic questions about their practice in section (5) of the survey. Data are
reported in the number of respondents (n) to each question.


164

#### 165 Opinion and Use of Genetic Testing

166 The majority of survey respondents (86%; n=97) reported genetic testing being 'very relevant' in the

- 167 care of their patients. No survey respondents reported genetic testing being 'not at all relevant in the
- **168** care of their patients'. Figure 1 delineates responses to this question on the relevance of genetic
- 169 testing in the care of patients by provider-reported specialty. Of those respondents who answered
- **170** genetic testing is either 'somewhat relevant' (9.8%; n=11) or 'slightly relevant' (3.6%; n=3) in the
- 171 care of their patients, provider specialties included electrophysiology, interventional cardiology, fetal
- 172 cardiology, general cardiology, cardiac ICU, and imaging.
- 173

#### PI: Sierra Pond IRB Exemption: 00164238



174175 FIGURE 1. Provider Opinions on the Relevance of Genetic Testing

176 Responses to survey question 1 "How relevant is genetic testing in your care of patients" are delineated by provider
177 specialty.

178

179 The ordering trends of a few key specialists stood out and were investigated further:

180 electrophysiologists, interventional cardiologists, and general cardiologists. These trends were groups

181 or providers who reported either they consistently ordered genetic testing routinely or not at all. The

**182** findings of all providers and their reported use of genetic testing are depicted in Figure 2. Of

183 electrophysiologists, ninety-six percent reported ordering genetic testing at least a few times per year

184 at minimum. As expected, a high percentage, 80%, of electrophysiologists reported ordering genetic

185 testing at least a few times per month. Interventional cardiologists were on the other end of the


186 spectrum regarding ordering trends: fifty-seven percent of interventional cardiologists reported187 never ordering genetic testing or stated they did not know how often they order genetic testing.

188 General cardiologists were somewhere in the middle with their ordering trends: seventy-five percent

189 of general cardiologists reported ordering genetic testing a few times per year or never.

190

#### PI: Sierra Pond IRB Exemption: 00164238



191

**192 FIGURE 2.** Provider Reported Use of Genetic Testing

193 Responses to survey question 11 "How often do you order genetic testing for your patients" are delineated by provider 194 specialty.

195

#### 196 Reported Barriers to Genetic Testing

**197** Respondents were asked to report their comfort level with activities related to genetic testing

**198** including navigating insurance authorization and billing, interpreting genetic testing results for

199 heritable cardiac conditions, and ability to communicate the results of genetic testing to patients.

200 Thirty-five percent (n=39) of respondents reported being 'uncomfortable' with navigating insurance

201 authorization and billing procedures. Based on respondents' answers to this survey questions, we

propose the ability to navigate insurance authorization and billing procedures is a potential barrier to

203 the use of genetic testing by cardiovascular providers.

204

205 Genetic test interpretation and communication of genetic test results were not identified as being

significant sources of provider discomfort. When respondents were asked to rank their comfort


207 with interpreting genetic test results for heritable cardiac conditions based on previous training,

208 thirty-six percent36% (n=40) stated they were 'somewhat comfortable'. In response to a comfort

209 level with communication of genetic testing results to the patient, thirty-eight percent38% (n=43) of

- 210 respondents stated they were 'somewhat comfortable'. These results are summarized in Figure 3.
- 211

#### PI: Sierra Pond IRB Exemption: 00164238



#### 212 213

FIGURE 3. Reported Comfort Level with Activities Related to Genetic Testing

214 Responses to questions in section (4) of the survey regarding provider comfort with activities related to genetic testing 215 are reported by percentage of respondents.

216

#### 217 Influence of Provider Demographics on Genetic Testing

218 Statistical analyses were performed to determine if any particular demographic attributes of a

219 provider influenced their reported opinion of, use of, or perceived barriers to the use of genetic

testing. These findings are summarized in Table 2. Most significantly, we found that the provider's

specialty had an impact on how often they reported ordering genetic testing in practice as well as

- their reported comfort level with interpreting genetic test results for heritable cardiac conditions. In
- addition, we determined the provider's geographic work setting had an impact on how often they
- reported ordering genetic testing in practice. Interestingly, provider geographic work setting also
- influenced opinion of genetic testing's value for screening at-risk family members and for
- 226 medication and device management.
- 227

228 229

Statement	P□
Provider specialty significant trends	
How often do you order genetic testing for your patients?	< 0.001
Do you know where your practice sends genetic test samples for analysis?	< 0.001
Comfort with interpreting genetic testing results for heritable cardiac conditions based on your previous training.	< 0.001
Comfort with communication of genetic testing results to the patient.	< 0.001
Provider work setting significant trends	
How often do you order genetic testing for your patients?	< 0.001
Genetic testing is valuable for screening at-risk family members.	< 0.001
Genetic testing for cardiac patients is valuable for medication and device management.	< 0.001
My practice has a genetics professional on staff with whom my patients can meet.	< 0.001
<b>TABLE 2.</b> Provider Opinions on the Utility, Use, and Barriers of Genetic Tes $\Box$ : Chi-squared test with Bonferroni Correction (0.05/22; P<0.0022)	ting in Practice

PI: Sierra Pond IRB Exemption: 00164238

#### 230 DISCUSSION

231 Our study revealed that cardiovascular providers consider genetic testing relevant to their practice, 232 which is important in understanding how to then implement it in practice. Guideline-directed 233 medical management increasingly informs patient care. The guidelines from international 234 organizations, such as the Heart Rhythm Society, have no specific legal territory and have no legally 235 enforcing character. Nonetheless, they represent the state-of-the-art recommendations for patient 236 diagnosis and management and set standards to which most practitioners aspire [20]. Our study tells 237 us that the importance of genetic testing is understood by clinicians, but barriers exist to fully 238 incorporating genetic testing into patient care. This study has practical applications regarding 239 improvements to the uptake of genetic testing in cardiovascular medicine. Overall, the findings of 240 this study suggest cardiovascular provider specialty impacts how often genetic testing is ordered in 241 practice. The findings also suggest provider work setting impacts how often genetic testing is 242 ordered in practice, provider opinion of the utility of genetic testing for family screening, and 243 provider opinion on the utility of genetic testing for medication and device management. For 244 example, in the case of potentially lethal and treatable conditions such as catecholaminergic 245 polymorphic ventricular tachycardia (CPVT) or long OT syndrome (LOTS), it is the responsibility 246 of the physician, preferably in conjunction with an expert genetics team, to communicate to the 247 patient/family the critical importance of family screening, whether this be facilitated by cascade 248 genetic testing or by broader clinical family screening [20]. Interestingly, the age range of patients a 249 cardiovascular provider sees does not impact their opinion of, use of, or access to genetic testing. 250 However, it should be noted that the sample size and queried population may have impacted this

251 252 finding.

253 Based on the results of this study, navigating insurance authorization and billing procedures was an 254 identified area of discomfort for cardiovascular providers. We suggest this as a targeted area for 255 future cardiovascular provider education. This aligns with findings from other studies in the field 256 [28, 32]. Designing educational materials that address the hurdles of insurance and billing is likely to 257 be a useful strategy in addressing this area of concern for cardiovascular providers in the United 258 States. Recommendations could be made for partnering with genetic counselors or local 259 communities such as the SADS Foundation to help providers better understand insurance coverage. 260 Automated modules about insurance or clear pathways of communication with genetic testing strategies could be useful in addressing this.

261 262

263 Interestingly, our study did not find significant provider discomfort in interpreting genetic testing. 264 This could be due to the large majority of providers representing the specialty of electrophysiology. 265 This group of providers has a longstanding history of utilizing genetic testing in patient care and 266 understanding the underlying causes of inherited arrhythmias is an important component of clinical 267 care. Other studies in the field [28, 32] have found provider discomfort with interpretation. Eighty 268 percent of respondents (n=89) to this survey stated they would be interested in further training and 269 education regarding genetic testing interpretation should their schedules allow, and 45% (n=50) 270 stated they would be 'likely' to participate in an online webinar on genetic testing interpretation if 271 prompted. Expanding the population size surveyed may reveal concerns about test interpretation, 272 but from our evaluation, cardiologists specializing in electrophysiology as a group feel comfortable 273 with genetic test results interpretation.

274

275 A limitation of this study was the limited sample size that was primarily comprised of

276 electrophysiologists from urban university medical centers. This population is likely to have a self-

PI: Sierra Pond IRB Exemption: 00164238

- 277 reporting bias since we primarily contacted providers who associate with the SADS Foundation, a
- 278 patient advocacy group that widely promotes genetic testing. The homogenous population of survey
- 279 respondents limits the conclusions and applications that can be drawn from these results. It should
- also be noted that the survey developed and implemented in this study is not a validated tool and
- results from survey questions should be analyzed with this in mind.
- 282

### 283 CONCLUSION

- The need for genetic testing in cardiovascular medicine has been clearly defined and is part of the most recent expert consensus documents[20]. While respondents to this survey clearly acknowledge the relevance of genetic testing in the care of their patients, significant genetic testing care gaps for patients with heritable genetic testing conditions remain with few patients undergoing recommended genetic testing during their cardiac evaluation. This research captures certain provider characteristicsspecialty and geographic work setting- that influence genetic testing ordering and uptake. Further research is needed to understand how to best address the disconnect between opinion and the use
- 291 of genetic testing, and to continue improving the uptake of genetic testing for patients with
- 292 inherited cardiac conditions.

# 293294 REFERENCES

- Walsh, R., et al., Evaluation of gene validity for CPVT and short QT syndrome in sudden arrhythmic
   *death.* Eur Heart J, 2022. 43(15): p. 1500-1510.
- 297 2. Priori, S.G. and C.A. Remme, *Inherited conditions of arrhythmia: translating disease mechanisms to patient management*. Cardiovasc Res, 2020. **116**(9): p. 1539-1541.
- 3. Ingles, J., et al., Genetic Testing in Inherited Heart Diseases. Heart Lung Circ, 2020. 29(4): p. 505511.
- 301 4. Stafford, F., et al., The role of genetic testing in diagnosis and care of inherited cardiac conditions in a specialised multidisciplinary clinic. Genome Med, 2022. 14(1): p. 145.
- 303 5. Spoonamore, K.G. and S.M. Ware, Genetic testing and genetic counseling in patients with sudden death
  304 risk due to heritable arrhythmias. Heart Rhythm, 2016. 13(3): p. 789-97.
- 305 6. Futema, M., et al., Genetic testing for familial hypercholesterolemia-past, present, and future. J Lipid Res,
  306 2021. 62: p. 100139.
- 307 7. Knight, L.M., et al., Genetic testing and cascade screening in pediatric long QT syndrome and hypertrophic
   308 cardiomyopathy. Heart Rhythm, 2020. 17(1): p. 106-112.
- 309 8. Specterman, M.J. and E.R. Behr, *Cardiogenetics: the role of genetic testing for inherited arrhythmia*310 syndromes and sudden death. Heart, 2023. 109(6): p. 434-441.
- 311 9. Lioncino, M., et al., Hypertrophic Cardiomyopathy in RASopathies: Diagnosis, Clinical Characteristics,
  312 Prognostic Implications, and Management. Heart Fail Clin, 2022. 18(1): p. 19-29.
- 313 10. Harris, S.L. and M.E. Lindsay, Role of Clinical Genetic Testing in the Management of Aortopathies.
  314 Curr Cardiol Rep, 2021. 23(2): p. 10.
- 315 11. Kaufman, E.S., et al., Management of Congenital Long-QT Syndrome: Commentary From the Experts.
  316 Circ Arrhythm Electrophysiol, 2021. 14(7): p. e009726.
- 317 12. Brodie, O.T., Y. Michowitz, and B. Belhassen, *Pharmacological Therapy in Brugada Syndrome*.
  318 Arrhythm Electrophysiol Rev, 2018. 7(2): p. 135-142.
- Black, R.M., et al., Projected impact of pharmacogenomic testing on medications beyond antiplatelet
   therapy in percutaneous coronary intervention patients. Pharmacogenomics, 2020. 21(7): p. 431-441.
- 321 14. Ingles, J., et al., Guidelines for genetic testing of inherited cardiac disorders. Heart Lung Circ, 2011.
- **322 20**(11): p. 681-7.

PI: Sierra Pond IRB Exemption: 00164238

323 324 325 326	15.	Ackerman, M.J., et al., HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm, 2011. <b>8</b> (8): p. 1308-39.
327 328 329 330	16.	Wilde, A.A.M., et al., European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Europace, 2022. 24(8): p. 1307-1367.
331 332	17.	Lui, D.T.W., A.C.H. Lee, and K.C.B. Tan, <i>Management of Familial Hypercholesterolemia: Current Status and Future Perspectives</i> . J Endocr Soc, 2021. <b>5</b> (1): p. bvaa122.
333 334	18.	Baumgartner, H., et al., 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J, 2021. <b>42</b> (6): p. 563-645.
335 336 337 338	19.	Writing Committee, M., et al., 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Thorac Cardiovasc Surg, 2021. 162(1): p. e23-e106.
339 340 341 342	20.	Wilde, A.A.M., et al., European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the State of Genetic Testing for Cardiac Diseases. Heart Rhythm, 2022. <b>19</b> (7): p. e1-e60.
343 344	21.	Towbin, J.A., et al., 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm, 2019. <b>16</b> (11): p. e301-e372.
345 346	22.	Murdock, D.R., et al., Genetic testing in ambulatory cardiology clinics reveals high rate of findings with clinical management implications. Genetics in Medicine, 2021. <b>23</b> (12): p. 2404-2414.
347 348	23.	Cohen, J.K., Most Patients With Inherited Heart Conditions Not Getting Guideline-Backed Genetic Testing. Precision Medicine Online, 2023.
349 350	24.	Sturm, A.C., et al., <i>Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel.</i> J Am Coll Cardiol, 2018. <b>72</b> (6): p. 662-680.
351 352	25.	Longoni, M., et al., Real-world utilization of guideline-directed genetic testing in inherited cardiovascular diseases. Front Cardiovasc Med, 2023. <b>10</b> : p. 1272433.
353 354	26.	Dusic, E.J., et al., <i>Barriers, interventions, and recommendations: Improving the genetic testing landscape.</i> Front Digit Health, 2022. <b>4</b> : p. 961128.
355 356	27.	Smith, H.S., et al., <i>Patient and Clinician Perceptions of Precision Cardiology Care: Findings From the HeartCare Study.</i> Circ Genom Precis Med, 2022. <b>15</b> (6): p. e003605.
357 358	28.	Lopez Santibanez Jacome, L., et al., <i>Practitioners' Confidence and Desires for Education in Cardiovascular and Sudden Cardiac Death Genetics.</i> J Am Heart Assoc, 2022. <b>11</b> (7): p. e023763.
359 360	29.	Aatre, R.D. and S.M. Day, <i>Psychological issues in genetic testing for inherited cardiovascular diseases.</i> Circ Cardiovasc Genet, 2011. <b>4</b> (1): p. 81-90.
361 362 363	30.	Harris, P.A., et al., Research electronic data capture (REDCap)a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform, 2009. <b>42</b> (2): p. 377-81.
364 365	31.	Harris, P.A., et al., The REDCap consortium: Building an international community of software platform partners. J Biomed Inform, 2019. 95: p. 103208.
366 367 368 369	32.	Spoonamore, K.G. and N.M. Johnson, Who Pays? Coverage Challenges for Cardiovascular Genetic Testing in U.S. Patients. Front Cardiovasc Med, 2016. <b>3</b> : p. 14.

PI: Sierra Pond IRB Exemption: 00164238


#### 370 ACKNOWLEDGEMENTS

- 371 This manuscript is based on a research project conducted by Sierra Pond to fulfill the requirements
- 372 of the University of Utah Master's Degree in Genetic Counseling. This project was made possible
- 373 by integral support from the Sudden Arrhythmia Death Syndromes (SADS) Foundation.
- 374


#### 375 FUNDING


376 This project was funded by the University of Utah Graduate Program in Genetic Counseling.

#### How relevant is genetic testing in your care of patients?



#### How often do you order genetic testing for your patients?





#### Provider Reported Comfort Level with Activities Related to Genetic Testing

Characteristics	Number of Respondents, N
Time in Practice	
Still in training	9
5 Years	8
5-10 Years	16
10-15 Years	20
>15 Years	58
tps //toi org/10. N0112024.05.15.24307347; this version posted May 15, 2024. The ied by peer review) is the author/funder, who has granted medRxiv a license to dis It is made available under a CC-BY 4.0 International license .	copyright holder for this preprint play the preprint in perpetuity.
Private Group Practice Private Solo Practice	0
University Medical Center	87
Private Hospital/Medical Facility Public Hospital/Medical Facility	9 7
Public Hospital/Medical Facility	
Diagnostic Laboratory/Testing Laboratory	0
Post Mortem	0
Other	1
Geographic Region of Work	22
Urban	92
Suburban	18
Rural	1
Provider Reported Specialty	
Electrophysiology	61
Heart Failure/Transplant	7
Interventional	7
Fetal Cardiology	6
Imaging	8
Pulmonary Hypertension	0
Dyslipidemia	0
CICU	3
General Cardiology	12
Cardiothoracic Surgery	1
Other, Not Listed	6
Age Range of Patients Seen	
Pediatrics	36
Adult	25
Both Pediatric and Adult	48
Prenatal	2

## Statement

# Provider specialty significant trends

< 0.001How often do you order genetic testing for your patients? Do you know where your practice sends genetic test samples for analysis? < 0.001 Comfort with interpreting genetic testing results for heritable cardiac conditions based on your previous training. < 0.001Comfort with communication of genetic testing results to the patient. < 0.001Provider work setting significant trends How often do you order genetic testing for your patients? < 0.001 Genetic testing is valuable for screening at-risk family members. < 0.001Genetic testing for cardiac patients is valuable for medication and device management. < 0.001 My practice has a genetics professional on staff with whom my patients can meet. < 0.001

Pa